Posted: 22 December 2023
Biointelect is delighted to wrap up 2023 by announcing the appointment of Leah Goodman as Chief Executive Officer. Leah will lead the organisation through its next exciting period of strategic growth cementing our unique position in full value chain offering, for innovative clients from research to commercialisation.
Jenny Herz, Biointelect Co-founder said “I am thrilled that Leah, with her strong leadership, diverse healthcare background and strategic experience is joining Biointelect for this exciting period of our company lifecycle. Biointelect’s vision is to increasingly play an important part in enabling the healthcare ecosystem for medical innovation, and Leah joining as CEO at this time will leverage both her strong industry knowledge and networks, and expansive leadership experience in company growth strategy and execution to enable our vision”.
Leah holds a Bachelor of Science and Master of Commerce, both from the University of NSW and has her GAICD accreditation. She has significant experience successfully leading Multinational company business transformation and growth in Australia and across Asia including South East Asia, Korea and Japan, most recently resigning from the Managing Director role at Bristol-Myers Squibb returning home to Sydney for family reasons.
Across her roles Leah has contributed to shaping the Australian Life Science industry through advocating for faster access to innovative medicines including pioneering disruptive approaches to government to decrease delay from registration, an increased respect for the patient role in decision making, and for improved access for clinical trials, both in company leadership roles and as an active member of the Medicines Australia Board and community. Leah’s passion for Industry discussion on the wider value of industry investment to the economy has recently contributed to the formation of a MA Special Interest Group on this topic.
Leah’s experience spans commercialisation of varied innovative treatments across oncology and immunooncology, gene therapies, immunotherapies, antimicrobials, diabetes, cardiovascular disease, neurology, as well Generic Medicines and OTC medicines.
Ms Herz added that “Leah’s previous experience with NSW Health in establishing RNA and Viral Vector technologies’ manufacturing capabilities gives her a diverse background which, combined with her successful commercial leadership and healthcare industry experience, is a welcome addition to the Biointelect team and further strengthens the Biointelect partnership offering to our customers”.
